Publication: Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer
Authors
Ditsch, Nina ; Toth, Bettina ; Himsl, Isabelle ; Lenhard, Miriam ; Ochsenkühn, Robert ; Friese, Klaus ; Mayr, Doris ; Jeschke, Udo
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
There is evidence that breast cancer patients
suffer from thyroid disorders. However, the relation
between thyroid receptor (TR) expression and breast
cancer remains unknown so far. Therefore, the aim of
this study was an immunohistochemical analysis of TR
expression in breast cancer patients.
Materials and methods: The expression of the
combined antibody TRalpha1 and 2 and TRalpha1 or 2
alone as well as the expression of combined TRbeta1
and 2 and TRbeta1 or 2 alone was investigated with
specific monoclonal or polyclonal antibodies in 82
patients. All patients presented with a first diagnosis of
sporadic breast cancer. The ABC method was used for
staining and staining intensities were analyzed using the
IRS score.
Results: Both TRalpha and TRbeta were expressed
in the nuclei of breast cancer cells. In 24% (28/78) of the
slides TRalpha1 and 2 IRS was positive. Immunopositivity
for TRalpha1 was found in 55/78 slides, for
TRalpha 2 in 54/79 slides (71 and 68%, respectively).
The expression of TRbeta1 and 2 showed a positive
detection in 33/77 (43%) of the slides, for TRbeta1 it
was 43/79 (54%), for TRbeta2 60/76 (79%).
Significant correlations of the expression of TRs -
especially TRalpha2 - were found with further
prognostic histopathological parameters such as tumor
size, axillary lymph node involvement, grading and
hormone receptor status. Multivariate analysis showed a
trend for TRalpha2 as an independent predictor of
disease-free and overall survival.
Discussion: Our results revealed specific alterations
in the expression of TRs - especially of TRalpha2 - in
breast cancer patients, suggesting it as a marker with
possible prognostic validity.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.